Optimapharm d.o.o
Optimapharm d.o.o is recorded as a service provider in 21 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 21 trials · Latest update first
A randomized, double-blind, multi-center, placebo-controlled, parallel-group phase 3 study to compare the efficacy, acceptability, and safety of Tranexamic Acid Oral Solution 5% with placebo in the prevention of clinically relevant bleeding events in subjects treated with direct oral anticoagulants or vitamin K antagonists and undergoing a single or multiple tooth extraction
Sponsor Hyloris Developments
- Start (EU)
- Latest update
- Estimated end
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)
Sponsor Celldex Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
Sponsor Genzyme Corp.
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella B)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, Double-Blind, Randomised, Placebo-Controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-Free Diet
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
Randomized, Double-Blind, Parallel-Group, Adaptive, Three-arm, Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC)
Sponsor Airway Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)
Sponsor Aplagon Oy
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib and tislelizumab in patients with advanced/metastatic colorectal cancer
Sponsor Oncomatryx Biopharma S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU2)
Sponsor Celldex Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtecan as Induction Treatment for HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer Patients (The DEMETHER Study)
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 3, double-blind, placebo-controlled, multicentre study on the efficacy and safety of human plasma derived antithrombin (Atenativ) in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass
Sponsor Octapharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS).
Sponsor Fundacio Sant Joan De Deu
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU1)
Sponsor Celldex Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.
Sponsor Polypid Ltd.
- Start (EU)
- Latest update
- Estimated end
TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of first line treatment in transplant eligible multiple myeloma patients
Sponsor North Estonia Medical Centre Foundation
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA
Sponsor Solti Group
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)
Sponsor GB002 Inc.
- Start (EU)
- Latest update
- Estimated end
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
Sponsor Dr Reddy's Laboratories Limited
- Start (EU)
- Latest update
- Estimated end
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
Sponsor Oncomatryx Biopharma S.L.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
Sponsor Adeptio Pharmaceuticals Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Optimapharm d.o.o?
The 2026-10-09 snapshot links Optimapharm d.o.o to 21 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Safety reporting & pharmacovigilance, among 18 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Optimapharm d.o.o?
The most frequently recorded therapeutic areas are Immunology, Solid Tumor Oncology, Allergy, Dermatology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Optimapharm d.o.o conducted?
The linked trials record locations in 25 countries, including Spain, Poland, Germany, Italy, Czechia. These are trial locations, not confirmed office locations or countries where Optimapharm d.o.o delivered services.
What can this page tell me about Optimapharm d.o.o's trial experience?
Browse 21 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Optimapharm d.o.o. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Optimapharm d.o.o.